JonesJK: Broader Uses of Post Marketing Surveillance in Drug Development, Regulatory Assessment, and Postmarketing Surveillance. WardellWMVeloG. (eds): Plenum Press, New York, 1980.
2.
Postmarketing Surveillance of Prescription Drugs, Office of Technology Assessment, Congress of the United States, November 1982.
3.
RossiACKnappDEAnelloC.: Discovery of adverse drug reactions. JAMA1983; 249:2226.
4.
BlackwellB.StolleyPDBuncherR.: Phase IV investigations. Clin Pharmacol Therap1975; 18:653.
5.
BellRLSmithEO: Clinical trials in postmarketing surveillance of drugs. Controlled Clin Trials1982; 3:61.
6.
Report on Joint Commission of Prescription Drug Use, Appendix 111B, Food and Drug Administration, Rockville, MD1980.
7.
ShubinS.: Triazure and public drug policies. Perspect Biol Med1979; Winter: 185–204.
8.
WardellWMTsiancoMCAnavekarSN: Postmarketing surveillance of new drugs: II. Case studies. J Clin Pharmacol1979; 19:169.
9.
RauchEF: Data entry experience with the Flexeril® surveillance program. Drug Inf J1979; July-September:75–83.
Workgroup to the Postmarketing Task Force, Food and Drug Administration. A review of elected phase IV studies and their contributions to postmarketing surveillance, available from Freedom of Information (HFI-35). Rockville, MD Bureau of Drugs, 1982.
12.
RossiACKnappDEAnelloC.: Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods. JAMA1983; 249:2226.
13.
GiffordLMAeugleMEMyersonRM: Cimetidine postmarket outpatient surveillance program. Interim report on phase I. JAMA1982; 243:1532.
14.
HumphriesTJMyersonRMGiffordLM: A unique postmarket outpatient surveillance program of Cimetidine: Report on phase II and final summary. Am J Gastroenterol1984; 79:593.
15.
JickJ.BrandtDE: Allopurinol and cataracts. Am J Ophthalmol1984; 98:355.
